Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: Analysis of microbial diversity in ECZTRA 1, a randomized controlled trial
Lisa A. Beck(University of Rochester Medical Center), Amy S. Paller(Northwestern University), Hidehisa Saeki(Nippon Medical School), Mads A. Røpke(Leo Pharma (Denmark)), Petra Arlert(Leo Pharma (Denmark)), M. Tauber(Inserm), Lawrence F. Eichenfield(University of California San Diego), Alan D. Irvine(Trinity College Dublin), Stephan Weidinger(Technical University of Munich), Thomas Werfel(Medizinische Hochschule Hannover), Jiang Li(Jiangsu University), Thomas Bieber(University of Bonn)
Cited by 51
Related Papers
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
EAACI Food Allergy and Anaphylaxis Guidelines: diagnosis and management of food allergy
|Allergy|2014|1.4k
Guidelines of care for the management of atopic dermatitis
|Journal of the American Academy of Dermatology|2013|1.3k
Guidelines of care for the management of atopic dermatitis
|Journal of the American Academy of Dermatology|2014|1.2k